Literature DB >> 22775439

BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.

E Richtig, D Schrama, S Ugurel, I Fried, A Niederkorn, C Massone, J C Becker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22775439     DOI： 10.1111/j.1365-2133.2012.11121.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

1.  Cardiac surgery for metastatic melanoma.

Authors:  Ingeborg M Keeling; Igor Knez; Erika Richtig; Robert Zweiker; Ariane Aigelsreiter; Drago Dacar
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 2.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

3.  NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

Authors:  Arnaud Uguen; Matthieu Talagas; Sebastian Costa; Laura Samaison; Laure Paule; Zarrin Alavi; Marc De Braekeleer; Cédric Le Marechal; Pascale Marcorelles
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

4.  Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.

Authors:  L Heinzerling; S Kühnapfel; D Meckbach; M Baiter; E Kaempgen; P Keikavoussi; G Schuler; A Agaimy; J Bauer; A Hartmann; F Kiesewetter; R Schneider-Stock
Journal:  Br J Cancer       Date:  2013-04-11       Impact factor: 7.640

5.  Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

Authors:  Lucile Boursault; Véronique Haddad; Béatrice Vergier; David Cappellen; Severine Verdon; Jean-Pierre Bellocq; Thomas Jouary; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

6.  Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.

Authors:  L Heinzerling; M Baiter; S Kühnapfel; G Schuler; P Keikavoussi; A Agaimy; F Kiesewetter; A Hartmann; R Schneider-Stock
Journal:  Br J Cancer       Date:  2013-11-05       Impact factor: 7.640

Review 7.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.